Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01158417 · ClinicalTrials.gov registry record · NA
Resveratrol in Type2 Diabetes and Obesity
A NA study, sponsored by University at Buffalo.
- Terminated
- Registry status
- NA
- Development phase
- 15
- Enrollment target
NCT01158417: Clinical Trial NA study, sponsored by University at Buffalo.
NCT01158417 is a NA study that was terminated before completion, run by University at Buffalo. The registered enrollment target is 15 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01158417, a NA study, was terminated before completion, sponsored by University at Buffalo.
- TERMINATED
- Registry status
- NA
- Development phase
- 15 participants
- Enrollment target
Study Summary
The main objective of this study is to investigate the effect of resveratrol (plant derived food supplement) on inflammatory mediators and insulin resistance at the cellular and molecular level in obese non diabetic and type 2 diabetic subjects in vivo.
Primary Outcome
To investigate the effect of resveratrol on ROS generation and the pro-inflammatory transcription factor NF-kB
Interventions
- DRUG Placebo
- DRUG Resveratrol 40 mg oral three times a day
- DRUG Resveratrol 500 mg oral once daily.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2008-12 |
| Est. Completion | 2012-07-08 |
| Phase | NA |
Why NCT01158417 stopped before completion
NCT01158417 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01158417 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01158417 about?
NCT01158417 is a clinical study titled "Resveratrol in Type2 Diabetes and Obesity". The main objective of this study is to investigate the effect of resveratrol (plant derived food supplement) on inflammatory mediators and insulin resistance at the cellular and molecular level in obese non diabetic and type 2 diabetic subjects in vivo.
What is the current status of trial NCT01158417?
This trial is currently terminated. It is a NA study. The enrollment target is 15 participants. The study started on 2008-12. Estimated completion is 2012-07-08.
What interventions are being tested in trial NCT01158417?
The interventions under investigation include: Placebo (DRUG), Resveratrol 40 mg oral three times a day (DRUG), Resveratrol 500 mg oral once daily. (DRUG).
Who is sponsoring clinical trial NCT01158417?
This trial is sponsored by University at Buffalo, which has 67 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01158417's enrollment target sits among peer trials
15 1881st of 2000 higher than 92 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia